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Abstract. Vitiligo is a disorder causing skin depigmenta-
tion, in which several factors have been proposed for its 
pathogenesis: Environmental, genetic and biological aspects 
of melanocytes, even those of the surrounding keratinocytes. 
However, the lack of understanding of the mechanisms has 
complicated the task of predicting the development and 
progression. The present study used microarray analysis to 
characterize the transcriptional profile of skin from Vitiligo 
Vulgaris (VV) patients and the identified transcripts were 
validated using targeted high-throughput RNA sequencing in 
a broader set of patients. For microarrays, mRNA was taken 
from 20 skin biopsies of 10 patients with VV (pigmented and 
depigmented skin biopsy of each), and 5 biopsies of healthy 
subjects matched for age and sex were used as a control. A 
signature was identified that contains the expression pattern 
of 722 genes between depigmented vitiligo skin vs. healthy 
control, 1,108 between the pigmented skin of vitiligo vs. 
healthy controls and 1,927 between pigmented skin, depig-
mented vitiligo and healthy controls (P<0.05; false discovery 
rate, <0.1). When comparing the pigmented and depigmented 
skin of patients with vitiligo, which reflects the real difference 
between both skin types, 5 differentially expressed genes were 
identified and further validated in 45 additional VV patients 
by RNA sequencing. This analysis showed significantly higher 
RNA levels of calpain-3, dopachrome tautomerase, melan-A 
and tyrosinase-related protein-1 genes. The data revealed that 
the pigmented skin of vitiligo is already affected at the level 
of gene expression and that the main differences between 
pigmented and non-pigmented skin are explained by the 
expression of genes associated with pigment metabolism.
Introduction
Vitiligo is a skin disease characterized by the lack of pigmen-
tation in the skin, it affects approximately 0.1 to 2% of the 
world population. However, its prevalence varies considerably 
among populations and ethnic groups: 0.14% in Russia, 1% in 
USA, and 2.5% in Japan (1), although the highest incidence has 
been described in Mexico (4%) and India (8.8%) (1,2). The most 
common clinical variant of vitiligo is vitiligo vulgaris (VV), in 
which the patient presents asymptomatic, well-circumscribed, 
milky-white macules involving one or multiple body regions 
or segments (3). The lack of pigmentation could be attributed 
to two main causes: a) the absence of melanocytes, which are 
dendritic cells derived from the neural crest that migrates to the 
epidermis and then to the hair follicle during embryogenesis, 
or b) the inability of these cells to produce and store melanin 
in melanosomes in the process of melanogenesis (4). In this 
context, the pathological origin of vitiligo has not yet been 
fully understood. Several hypotheses and theories have been 
developed to explain these depigmentation processes (5-8).
Although melanocyte is responsible for the pigmentation 
process in vertebrates (9), the significance of the surrounding 
environment has been neglected, e.g., keratinocytes (8,10). 
Currently, it is known that the signaling mechanism that acti-
vates the route of melanogenesis is controlled by genes, whose 
products act as enzymes, structural proteins, transcriptional 
regulators, transporters, receptors and growth factors related 
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to the melanogenesis process (11). Some of the hormones and 
products from the hypothalamic-pituitary-adrenal axis, and 
their respective receptors and negative regulators, trigger a 
nuclear signaling cascade that leads to the activation or repres-
sion of tyrosinase, a key enzyme in the pigmentation process, 
including the final amount of melanin produced (12,13). 
A major hormone regulator in melanin synthesis is the 
α-melanocyte-stimulating hormone (α-MSH), produced by 
pituitary gland, which interacts with a specific cell surface 
receptor [Melanocortin 1 Receptor (MC1R)] to stimulate 
melanin synthesis and other differentiated melanocyte func-
tions (11).
Today, knowledge about genes and signaling path-
ways potentially involved in the development of vitiligo is 
increasing (14-17); for example, the expression profile of 
approximately sixteen thousand genes, in an in vitro culture 
of melanocytes obtained from five subjects with vitiligo, 
was analyzed using microarrays (17), describing five routes 
involved in the development of this disease: i) Development 
of melanocytes; ii) intracellular processing and vesicular traf-
ficking of tyrosinase gene family protein; iii) packaging and 
transport of melanosomes; iv) cell adhesion; and v) processing 
and presentation of antigens (17).
In addition, previous reports of gene expression involved 
in the melanocortin system (14) and melanogenesis signaling 
pathways (15) showed modified expression levels of proopi-
omelanocortin (POMC), melanocortin 1 receptor (MC1R), 
melanocortin 4 receptor (MC4R), tyrosinase-related protein 
1 (TYRP1) and dopachrome tautomerase (DCT), among 
other genes, in tissue affected by vitiligo when compared with 
healthy tissue samples from patients with vitiligo and normal 
skin from controls.
To date, there are few studies that involve the complete 
tissue analysis of patients with vitiligo. The identification 
of the expression profile of genes potentially involved in the 
development of the disease will be useful in understanding the 
molecular mechanism of its development to select potential 
therapeutic targets for its specific treatment.
In this study, we used microarray analysis to characterize 
the transcriptional profile of the skin of patients with VV 
and the identified transcripts were validated by the use of 
high-throughput RNA sequencing in a larger set of patients to 
determine the expression pattern that could play a role in the 
pathogenesis of vitiligo and the clinical types of this disease.
Materials and methods
Selection of participants. Fifty‑five Northeastern Mexican 
patients from the states of Coahuila, Nuevo Leon, San Luis 
Potosi, Tamaulipas, and Zacatecas were recruited between 
November 2009 and May 2015 at the Dermatology Department 
of the University Hospital-UANL, in Monterrey, Nuevo Leon, 
Mexico. The Ethics and Research Committee of the Faculty 
of Medicine-UANL approved and registered the protocol and 
forms of informed consent under the code DE08-008 and 
DE13-001. After signing their informed consent, the patients 
were interviewed and evaluated to confirm the diagnosis of VV. 
Five healthy controls were also included for the Microarray 
analysis. None of VV patients had received any specific treat-
ment in the previous six months to recruitment. The stage of 
VV (active AVV/stable SVV) was determined by intervals of 
time in the manifestation of new depigmented areas (stable 
vitiligo with lesional stability of >1 year), or enlargement of 
the already existing ones.
Sample collection and processing. Two skin biopsies of 4 mm 
were obtained from each patient with vitiligo. The first biopsy 
was obtained from the central part of the affected skin (called 
depigmented vitiligo skin) and the second from the healthy 
areas of the skin of patients with vitiligo (called pigmented 
vitiligo skin), generally 3 cm from the affected skin. Only a 
skin biopsy was taken from healthy control subjects (called 
control skin).
The skin tissue from the biopsies was immediately 
suspended in 5 volumes of RNA Later Solution (Ambion; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA) after 
collection, and stored at 4˚C overnight. The next day, the 
supernatant was remove, and the samples were stored at ‑80˚C 
until the time for analysis.
Total RNA was isolated from the samples using the RNeasy 
fibrous tissue mini kit (Qiagen, Inc., Valencia, CA, USA) 
according to the manufacturer's instructions and quantified 
using a NanoDrop® ND-8000 spectrophotometer (Thermo 
Fisher Scientific, Inc., Wilmington, DE, USA) and Qubit® 
RNA BR Assay kit (Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). The quality/integrity of the extracted RNA was 
evaluated by an Experion Automated electrophoresis System 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Microarray assays. The biopsies taken from depigmented 
and pigmented skin from ten vitiligo patients (5 AVV and 
5 SVV) and a skin biopsy of each of the five healthy controls 
were analyzed. For each sample, 100 ng of total RNA 
was amplified, purified, fragmented and labeled using the 
GeneChip® IVT Express kit, (Affymetrix; Thermo Fisher 
Scientific, Inc.) according to the manufacturer's instructions. 
12.5 µg of fragmented and labeled target were hybridized 
with Affymetrix GeneChip® Human Gene u133 plus Array 
(Affymetrix; Thermo Fisher Scientific, Inc.), at 45˚C for 
16 h, on a GeneChip® Hybridization Oven 640 (Affymetrix; 
Thermo Fisher Scientific, Inc.), according to the manufac-
turer's recommendation. The hybridized arrays were washed 
and stained on a GeneChip® Fluidics Station 450, scanned on 
a GeneChip® Scanner 3000 7G (Affymetrix; Thermo Fisher 
Scientific, Inc.), and then CEL image data files were gener-
ated for each matrix.
Data analysis. CEL files were processed using the affy package 
in R (https://cran.r-project.org). Data were pre-processed 
using RMA and normalized using quantile-normaliza-
tion (18). t-test and F-tests were used to determine a P-value 
for differentially expressed genes between groups. P-values 
were adjusted for multiple tests using the False Discovery 
Rate (FDR) approach (19). Principal component analysis 
(PCA) was performed in R.
Annotation and functional analysis. Further information 
about the genes was obtained from NetAffx™ Analysis 
Center (http://www.affymetrix.com) and NCBI databases 
(http://www.ncbi.nlm.nih.gov).
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Functional annotation was performed by uploading 
the resulting gene list onto DAVID (20,21) (Database 
for Annotation, Visualization and Integrated Discovery, 
https://david.ncifcrf.gov/tools.jsp). Genes were mapped to 
KEGG-pathways and scored according to P-values (EASE 
Score, modified Fisher's exact test) and corrected for multiple 
testing according to the Benjamini-Hochberg False Discovery 
Rate correction provided by the DAVID tool.
TruSeq Targeted RNA Expression analysis. Skin biopsies from 
45 vitiligo patients (23 AVV and 22 SVV) were analyzed by 
TruSeq Targeted RNA Expression (Illumina, Inc., San Diego, 
CA, USA). RNA was obtained and cDNA was prepared 
with ProtoScript® Reverse Transcriptase (New England 
Biolabs, Ipswich, MA, USA) according to the manufacturer's 
instructions. RNA expression analysis was performed on an 
Illumina MiSeq with MiSeq® Reagent Kit v3 (150 cycle) and 
TruSeq® Targeted RNA Custom Panel Kit designed to detect 
the expression profile of the calpain 3 (CAPN3), dopachrome 
tautomerase (DCT), glycerol-3-phosphate dehydrogenase 1 
(GPD1), melan-A (MLANA) and tyrosinase-related protein 1 
(TYRP1). RNA-Seq data were analyzed within Base Space 
(https://basespace.illumina.com) using the tool TruSeq Targeted 
RNA. Count data were exported and normalized per sample 
by equalizing the total number of counts (multiplying by the 
average of the total counts per sample then dividing by the 
accumulated counts per sample).
Results
Microarray analysis. In the analysis performed on vitiligo 
samples using microarray analysis, we first compared whether 
the unaffected skin holds a higher similarity to healthy controls 
than to the affected skin of the patients; one of the pigmented 
skin samples from a vitiligo patient was discarded from the 
microarray analyses as it lacked sufficient quality to be used. 
A PCA and hierarchical clustering shows that the unaffected 
skin is more similar to vitiligo samples than to healthy controls 
(Fig. 1), suggesting that pigmented skin in vitiligo patients is 
already affected regardless of its clinical evidence.
Further analysis comparing the healthy controls vs. skin 
samples from vitiligo patients (de/pigmented tissue) confirmed 
the existence of a large number of hits (1,927 probes at FDR 
<0.1) (Fig. 2).
Then we compared different combinations of groups at 
FDR <0.1, showing that there are differences between the 
three groups, with altered expression patterns (over and under 
expressed) when analyzing the more than 25,000 genetic targets 
present in Affymetrix Gene Chip® Human Gene u133 plus 
Array. Further, we observed several changes when comparing 
the healthy controls and patients independent of sample type 
(pigmented or depigmented skin of patients with vitiligo) 
that reached the 1,927 probes (Table I). When comparing the 
pigmented tissue of vitiligo patients against healthy controls, the 
difference decreases to 1,108 (Table I). Surprisingly, the number 
decreases further to 722 when comparing the depigmented 
vitiligo samples to healthy controls (Table I). Finally, the differ-
ences are modest when comparing the vitiligo depigmented 
samples against pigmented asymptomatic tissue, consistent 
with the initial observation that the asymptomatic tissue is 
already compromised. Therefore, we focused on these minor 
differences between vitiligo samples and their healthy counter-
parts, observing the differences in the important components 
of pigmentation (Fig. 3). Moreover, we noted that the expres-
sion profile of these genes were similar to those from healthy 
controls. On the other hand, no relationship was found between 
expression pattern variations, gender, age, or type of vitiligo.
Functional Annotation of observed differences. Using the 
DAVID functional annotation tool, the genes identified in 
Figure 1. Overall variability of gene expression profiles. (A) Randomly selected 5,000 genes (rows) ranked by average expression, and samples (columns) 
grouped by hierarchical clustering. The vitiligo depigmented skin samples are indicated as ‘V’, and ‘P’ corresponding pigmented vitiligo skin from vitiligo 
patients. (B) First two principal components coordinate. The variability explained by each component is shown in labels. PCA, principal component analysis.
SALINAS-SANTANDER et al:  GENE EXPRESSION CHARACTERIZATION OF VITILIGO 2807
each comparison were grouped into functional categories such 
as alternative splicing processes, splice variants, DNA and 
RNA binding domains, transcription, and expression regula-
tion, amongs others (Table I). However, by focusing on the 
comparisons made between the pigmented and depigmented 
skin of vitiligo patients it becomes apparent that the mainly 
compromised genes are involved in the pigmentation process, 
finding groups of genes responsible for pigment production, 
granule and melanosome, melanogenesis, tyrosine metabo-
lism, melanin biosynthesis and metabolic process, all of these 
involved in the development of this disease (Fig. 3).
TruSeq targeted RNA Expression analysis expression vali-
dation patterns. Surprisingly, the main differences between 
asymptomatic and depigmented skin from vitiligo patients 
were narrowed to only six probes (Fig. 4), five of which corre-
spond to undrexpressed genes in vitiligo tissue samples, i.e., 
dopachrome tautomerase (id. 205338_s_at, 205337_at DCT;), 
melan-A (id. 206427_s_at MLANA), tyrosinase-related 
protein 1 (id. 205694_at TYRP1), calpain 3 (id. 211890_x_at 
CAPN3), and glycerol-3-phosphate dehydrogenase 1 
(id. 204997_at: GPD1). These genes have been mostly related 
to melanogenesis, tyrosine metabolism, and glycerophospho-
lipid metabolism. Therefore, these genes were selected for 
validation by targeted RNA-Sequencing.
The expression analysis performed on skin biopsies 
from 45 additional VV patients confirmed the existence of 
significant differences in the expression pattern of three genes 
involved in skin pigmentation: DCT, MLANA and TYRP1. 
In addition, CAPN3 was also significant, although at a lower 
level. In addition to microarray analysis, no relationship was 
identified between the variants in the patterns of expression, 
gender, age, or type of vitiligo. Moreover, in the case of the 
GAPD1 gene, no significant difference in the expression 
pattern between asymptomatic skin and vitiligo lesions was 
found by NGS when compared to previous observations using 
microarray analysis (Fig. 5).
Discussion
Most vitiligo studies conducted in the Mexican population are 
focused in demographics and clinical characteristics. To date, 
the molecular etiology and genetic factors interacting in the 
development of vitiligo within this population have not been 
considered.
Up to date, there has been only two expression studies of 
vitiligo using microarray technology. In the first study, mela-
nocyte culture in vitro from 5 samples of VV patients were 
analyzed (17); in addition to the small number of samples, 
it did not reflect the contribution of the skin's environment 
as it only represents the alterations of a single cellular type 
(melanocytes); further, the expression pattern could be modi-
fied under cell culture conditions. This report found altered an 
expression pattern of genes involved in the development and 
function of melanocytes, proposing an autoimmune response 
as a secondary event caused by the abnormal function of mela-
nocytes (17). In our study, we also observed some similarities in 
the expression pattern of genes involved in pigment synthesis, 
melanosome, granule pigment, cytoplasmic vesicles (possibly 
melanosomas), plus redox reaction processes related to diverse 
functions, including cell-cell recognition, cell-surface recep-
tors, muscle structure, and the immune system. However, our 
results reflect the expression profile of the whole skin.
In a second report, an expression study using the Smyth 
line from chicken, an avian model for human autoimmune 
vitiligo, the microarray analysis results support the multi-
factorial etiology of vitiligo, where inflammatory/innate 
immune activity and oxidative stress, and the adaptive 
immune response play a predominant role in melanocyte 
loss. The microarray analysis results provided comprehensive 
information at transcriptome level, supporting the multifac-
torial etiology of vitiligo, where, along with the apparent 
inflammatory/innate immune activity and oxidative stress, 
the adaptive immune response plays a predominant role in 
melanocyte loss (22).
In the biological context of the skin, the melanocyte 
represents less than ten percent of epidermal cells (23,24). The 
functional clustering analysis made using the DAVID database 
points towards the involvement of an altered functional group 
composed by genes involved in diverse biological processes, 
such as transcription and transcription regulation, transcrip-
tional repression, alternative splicing, and keratin filament. The 
observation that melanocytes are the main cell type affected 
in vitiligo does not rule out the participation of other cellular 
components of the skin in the development of this disease, as 
supported by the major affected pathways of pigment synthesis, 
packaging and transport of pigment, when the depigmented 
vitiligo tissue was compared with the pigmented skin of 
Figure 2. Comparison between controls and vitiligo lesions + asymp-
tomatic tissue from vitiligo patients. The differential expressed genes are 
shown in rows and samples in columns. Blue and red color shows down 
regulated ⁄upregulated genes respectively in Z‑score scale. V and P labels 
denote ‘vitiligo depigmented skin’ and ‘pigmented vitiligo skin’ from vitiligo 
patients samples respectively. Only genes with FDR <0.1 are shown.
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vitiligo. For this reason, and considering that keratinocytes are 
the predominant cell type in this tissue (25), their role could 
involve an important function in skin pigmentation (10,26). 
Even when the differences in expression patterns between 
a) pigmented skin and b) affected skin vs. control skin the same 
metabolic routes are affected, in the first case a greater number 
of genes are involved (Table I), these could be explained by 
compensatory mechanisms (14,27) in which the skin of the 
Table I. Inference of pathways involved in vitiligo, according to the probes that presented altered expression patterns (over and 
sub expressed).
Comparison/N Biological altered pathways
Vitiligo depigmented skin vs. vitiligo Alternative splicing/Splice variant
pigmented skin vs. controls (N=1,927) DNA‑binding/Nucleic acid binding/Zinc‑finger/Transcription factor
 and transcription regulation/Krueppel-associated box
 Metal-binding
 Phosphoprotein
 Krueppel-associated box
 Coiled coil
Vitiligo pigmented skin vs. controls (N=1,108) Alternative splicing/Splice variant
 Intracellular
 Krueppel-associated box
 Coiled coil
Vitiligo depigmented skin vs. controls (N=722) Keratin filament
 High sulphur keratin-associated protein
 Splice variant
 Krueppel-associated box
Vitiligo depigmented skin vs. vitiligo pigmented skin Melanosome/melanosome membrane
(N=6) Uncharacterised domain, di-copper centre
 Tyrosinase/Tyrosine metabolism
 Topological domain: Lumenal, melanosome
 Melanin biosynthesis/Melanogenesis
(N) Altered genetic target from of 25,000 targets present in Affymetrix GeneChip® Human Gene u133 plus Array.
Figure 3. Biological processes involved in skin pigmentation and development of vitiligo. On the left are presented routes in normal skin pigmentation process; 
on the right are represented the major routes detected as altered in skin of vitiligo subjects.
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vitiligo patient tends to stimulate pigmentation by regulating 
the expression factors involved in pigmentation, increasing or 
decreasing their expression to maintain skin homeostasis.
After analyzing the genes showing a different expression 
pattern, a group of 5 genes, involved in the melanogenic routes, 
intracellular cysteine proteases, and oxidative stress, were 
selected for validation by TruSeq Targeted RNA Expression 
analysis. The validation assays showed a differential expression 
tendency in four genes: CAPN3, DCT, MLANA and TYRP1. 
However, GPD1 was not found differentially expressed by 
NGS. These results are consistent with Regazzetti et al (28), 
whom validated a group of genes in skin biopsies from patients 
with vitiligo, finding low expression levels of MLANA, DCT, 
and TYRP1 in vitiligo skin lesions when compared to skin 
around the injured and uninjured (pigmented/asymptomatic) 
tissue.
The CAPN3 gene was under expressed in the skin of 
patients with vitiligo; previously, Stromberg et al reported 
that this gene was up regulated in melanocyte cultures 
obtained from vitiligo lesions (17). This gene encodes a 
large subunit of neutral calpain of protease 3 activated by 
muscle calcium, a heterodimer consisting of a large subunit 
and a small subunit is a major intracellular protease that is 
ubiquitously expressed in human tissues and other and other 
tissue‑specific isoforms. Its function on the skin is not clear, 
but it has been observed that CAPN3 variants can play a 
pro-apoptotic role in melanoma cells and its down regula-
tion, as observed in highly aggressive melanomas, could 
contribute to their progression (29). In melanocytic cells, 
CAPN3 expression may be regulated by MITF (30) which 
regulates a broad variety of genes whose functions range 
from pigment production (such as DCT, MC1R, MLANA, 
TYR and TYP1) to the cell-cycle regulation, migration and 
survival; moreover, MITF-mediated up regulation of CAPN3 
has been reported in melanoma (30).
The GPD1 gene encodes a member of the NAD-dependent 
glycerol-3-phosphate dehydrogenase protein family, playing a 
critical role in carbohydrate and lipid metabolism (31). Along 
with GPD2, the mitochondrial isoform, it constitutes a glyc-
erol phosphate shuttle that facilitates the transfer of reducing 
equivalents from the cytosol to the mitochondria, playing a 
crucial role in osmoregulation and redox balance (32). In our 
study, the microarray analysis showed the under expression 
of this gene in tissue from patients with vitiligo lesions. As a 
result of expression profile validation, made by RNA‑Seq in a 
number of samples, no significant differences were observed 
between the expression profiles of affected pigmented skin in 
vitiligo patients. However, we observed a higher expression in 
some of the samples that possibly participate in the oxidative 
stress response experienced by the skin cells of these patients, 
a mechanism that has been described in this disease. So far, 
the participation of this gene in vitiligo has not been explored.
In addition, NGS provides a better approach to gene 
expression profile analysis, as this technology enables high 
resolution research for all of the RNA present in a sample, 
including mRNA sequence and abundance (33). Its useful-
ness has been compared with microarray technology and 
Real‑Time PCR in the analysis of expression profiles (34-36); 
therefore, it has been used in transcriptome analysis in clinical 
research (36-39).
The analysis of expression by directed sequencing of 
RNA (RNAseq) has been helpful in the efficient evaluation 
of expression profiles of multiple genes in human patho-
logical and non-pathological conditions (40-43). In particular, 
RNAseq using NGS, not only shows the expression levels 
of a transcript, but the presence of isoforms in the samples 
analyzed (44). In patients affected by dermatological diseases 
such as psoriasis, systemic lupus erythematosus (45-47), and 
vitiligo, these tools are an excellent alternative inidentifying 
modified gene expression patterns in key routes of skin 
Figure 4. Comparison of six probes of healthy tissue and vitiligo lesion biopsies at FDR <0.1. Blue and red color represent down ⁄upregulated genes, respectively.
Figure 5. Comparison of asymptomatic and vitiligo lesion biopsies from RNA-Seq analysis for CAPN3, DCT, GAPD1, MLANA and TYRP1 gene. Data show 
expression profiles obtained from the validation of the 5 genes selected by microarray. Black and light blue color of the top corresponds to pigmented and 
depigmented vitiligo skin samples from vitiligo patients. Blue and red color is the down regulated ⁄upregulated genes.
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homeostasis, pigmentation, and cell survival at a low cost and 
reduced time in comparison to RT-qPCR.
In conclusion, we found alterations in the expression 
pattern of depigmented vitiligo lesions when compared to 
pigmented asymptomatic skin of vitiligo patients and against 
healthy control samples. These results reflect that even the 
clinically unaffected (pigmented) skin shows an impaired 
melanogesis process in a patient with vitiligo; the observed 
changes are related to processes regulating gene expression 
and splicing that eventually will end up in skin depigmentation 
by altering the levels of proteins involved in this process. Up 
regulated expression profiles detected by microarray analysis 
for CAPN3, DCT, MLAN-A and TYRP1 in VV patients was 
validated using NGS TruSeq Targeted RNA Expression anal-
ysis, and whose altered functions on pigment production, and 
possibly in melanocyte cell survival, affect skin pigmentation, 
thus suggesting that these tools are an excellent alternative 
in identifying the expression pattern of genes involved in the 
development of this disease. On the other hand, we did not 
find any differences in the gene expression profiles of active 
or stable VV.
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